Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27155743 | 0.90 | KDR (0.56) | KDRAAK1EGFRFLT1FLT4 | |
| SCHEMBL27155177 | 0.83 | EGFR (0.49) | KDREGFRMET | |
| Hydrochloric Acid SCHEMBL27154319 | 0.82 | EGFR (0.49) | KDREGFRMET | |
| SCHEMBL4045647 | 0.77 | KDR (0.77) | KDREGFRMAPK14 | |
| SCHEMBL1459924 | 0.73 | KDR (0.75) | KDREGFRMAPK14 | |
| SCHEMBL13575474 | 0.69 | HPGD (0.57) | MAPK14PRMT1 | |
| SCHEMBL4044308 | 0.68 | KDR (0.77) | KDREGFRMAPK14 | |
| SCHEMBL4053446 | 0.67 | KDR (1.00) | KDREGFRMAPK14 | |
| SCHEMBL12172265 | 0.67 | HTT (0.62) | MAPK14 | |
| SCHEMBL1460928 | 0.66 | KDR (1.00) | KDREGFRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12145948-B2 | Compounds and methods for modulating HER2 | IAMBIC THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240182494-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240132521-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145948-B2 | Compounds and methods for modulating HER2 | ERBB2, EGFR, ERBB3 | KDR 153/4885AAK1 976/4885EGFR 2/4885 |
| US-20240182494-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | ERBB2, EGFR, ERBB3 | KDR 153/4885AAK1 976/4885EGFR 2/4885 |
| US-20240132521-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | ERBB2, EGFR, ERBB3 | KDR 153/4885AAK1 976/4885EGFR 2/4885 |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | ERBB2, EGFR, ERBB3 | KDR 153/4885AAK1 976/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.